Experienced in Granulomatosis with Polyangiitis

Dr. Amber R. Khan

Rheumatology
2222 Greenhouse Rd, Suite 1300, 
Houston, TX 
Accepting New Patients
Offers Telehealth
Experienced in Granulomatosis with Polyangiitis
2222 Greenhouse Rd, Suite 1300, 
Houston, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Amber Khan is a Rheumatologist in Houston, Texas. Dr. Khan is rated as an Experienced provider by MediFind in the treatment of Granulomatosis with Polyangiitis. Her top areas of expertise are Ankylosing Spondylitis, Axial Spondyloarthritis (AxSpA), Rheumatoid Pneumoconiosis, and Rheumatoid Lung Disease. Dr. Khan is currently accepting new patients.

Her clinical research consists of co-authoring 4 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Rheumatology
Licenses
Internal Medicine in OH
Languages Spoken
English
Spanish
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Community Health Choice
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Nippon Life
  • INSURANCE PLAN
Oscar
  • EPO
  • HMO
  • PPO
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 17 Less Insurance Carriers -

Locations

2222 Greenhouse Rd, Suite 1300, Houston, TX 77084

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 1/2a Clinical Trial to Assess Safety of a Single IV Infusion of Autologous Adipose-derived Mesenchymal Stem Cells in Adults With Active Rheumatoid Arthritis
A Phase 1/2a Clinical Trial to Assess Safety of a Single IV Infusion of Autologous Adipose-derived Mesenchymal Stem Cells in Adults With Active Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: September 26, 2025
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: July 22, 2025
Intervention Type: Drug
Study Drugs: Baricitinib, TNF Inhibitor
Study Phase: Phase 4
A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: July 17, 2025
Intervention Type: Drug
Study Drugs: Baricitinib, TNF Inhibitor
Study Phase: Phase 4
A Multi-centre Long-term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis
A Multi-centre Long-term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis
Enrollment Status: Terminated
Publish Date: February 07, 2024
Intervention Type: Drug, Biological
Study Drugs: Otilimab, csDMARD
Study Phase: Phase 3
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
Enrollment Status: Terminated
Publish Date: November 30, 2023
Intervention Type: Drug, Biological
Study Drugs: Otilimab, Tofacitinib, csDMARDs
Study Phase: Phase 3
A Randomized, Double-blind, Parallel Group, Multicenter Study to Assess the Immunogenicity and Safety of Transitioning Subjects With Rheumatoid Arthritis to Biosimilar Rituximab (DRL_RI) or Continued Treatment With Rituxan® or MabThera®
A Randomized, Double-blind, Parallel Group, Multicenter Study to Assess the Immunogenicity and Safety of Transitioning Subjects With Rheumatoid Arthritis to Biosimilar Rituximab (DRL_RI) or Continued Treatment With Rituxan® or MabThera®
Enrollment Status: Completed
Publish Date: November 18, 2023
Intervention Type: Biological
Study Phase: Phase 3
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: October 12, 2023
Intervention Type: Drug
Study Drugs: Olokizumab, Methotrexate
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects With SLE
A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects With SLE
Enrollment Status: Terminated
Publish Date: April 12, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1, Randomized, Placebo-Controlled, Multiple- Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3361237 in Patients With Systemic Lupus Erythematosus
A Phase 1, Randomized, Placebo-Controlled, Multiple- Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3361237 in Patients With Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: March 04, 2021
Intervention Type: Drug
Study Phase: Phase 1
View 9 Less Clinical Trials

4 Total Publications

Association between C reactive protein and depression in a population of healthy adults: the Cooper Center Longitudinal Study.
Association between C reactive protein and depression in a population of healthy adults: the Cooper Center Longitudinal Study.
Journal: Journal of investigative medicine : the official publication of the American Federation for Clinical Research
Published: February 20, 2020
Similar Doctors
Advanced in Granulomatosis with Polyangiitis
Dr. Matxalen Amezaga-Urruela
Rheumatology
Advanced in Granulomatosis with Polyangiitis
Dr. Matxalen Amezaga-Urruela
Rheumatology

Kelsey-Seybold Medical Group, PLLC

8233 N Sam Houston Pkwy E, 
Humble, TX 
 (28.2 miles away)
713-442-2000
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Matxalen Amezaga-Urruela is a Rheumatologist in Humble, Texas. Dr. Amezaga-Urruela is rated as a Distinguished provider by MediFind in the treatment of Granulomatosis with Polyangiitis. Her top areas of expertise are Antisynthetase Syndrome, Eosinophilia-Myalgia Syndrome, Rheumatoid Arthritis (RA), and Mixed Connective Tissue Disease. Dr. Amezaga-Urruela is currently accepting new patients.

Advanced in Granulomatosis with Polyangiitis
Dr. Kalpita M. Hatti
Rheumatology
Advanced in Granulomatosis with Polyangiitis
Dr. Kalpita M. Hatti
Rheumatology

Rheumatology Partners Of Houston, PLLC

129 Vision Park Blvd, Suite 206, 
Shenandoah, TX 
 (30.9 miles away)
281-315-8130
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Kalpita Hatti is a Rheumatologist in Shenandoah, Texas. Dr. Hatti is rated as an Advanced provider by MediFind in the treatment of Granulomatosis with Polyangiitis. Her top areas of expertise are Rheumatoid Arthritis (RA), Necrotizing Vasculitis, Axial Spondyloarthritis (AxSpA), and Granulomatosis with Polyangiitis. Dr. Hatti is currently accepting new patients.

Advanced in Granulomatosis with Polyangiitis
Dr. Alfredo Sardinas
Rheumatology
Advanced in Granulomatosis with Polyangiitis
Dr. Alfredo Sardinas
Rheumatology

David P Ellent PLLC

8845 Six Pines Dr, Suite 200, 
Shenandoah, TX 
 (30.1 miles away)
281-440-5300
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Alfredo Sardinas is a Rheumatologist in Shenandoah, Texas. Dr. Sardinas is rated as an Advanced provider by MediFind in the treatment of Granulomatosis with Polyangiitis. His top areas of expertise are Rheumatoid Arthritis (RA), Granulomatosis with Polyangiitis, Eosinophilia-Myalgia Syndrome, and Antisynthetase Syndrome. Dr. Sardinas is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Khan's expertise for a condition
ConditionClose
    View All 8 Distinguished Conditions
    View All 13 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile